^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Adenocarcinoma
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Ceritinib (Zykadia ) is accepted for use within NHS Scotland

    Excerpt:
    Ceritinib (Zykadia ) is accepted for use within NHS Scotland...for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Chin Med J (Engl)
    Title:

    Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

    Published date:
    05/05/2023
    Excerpt:
    The amplification refractory mutation system revealed ALK-positivity. The final diagnosis was lung adenocarcinoma...a dose of 450 mg of ceritinib was orally administered once daily….Chest CT after one month (June 2021) of commencing treatment showed significant partial response changes compared to the previous CT [Figure 1C]...the patient was considered down-staged to clinical complete response (CR) after 7 cycles of ceritinib treatment....No metastasis was found in the lymph nodes and no cancer tissue was found in the resection margin (pathological analysis showed CR) [Figure 1F]...this study reported a case of stage IIIA-N2 ALK-positive NSCLC patient treated with ceritinib which illustrated the feasibility and remarkable clinical efficacy of ceritinib as neoadjuvant targeted therapy.
    DOI:
    10.1097/CM9.0000000000002403